SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
KNSA

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)

GB · Delayed Price · Currency is USD
Healthcare · Medical - Pharmaceuticals
$93.89+$0.36 (+0.38%)
 
Market cap
$7.38B
Insider Score
Health Score
Analyst consensus
Listed since
May 24, 2018
Market Cap$7.38B+125.8%
Revenue (ttm)$945.96M+58.2%
Net Income$109.57M+205.1%
EPS$1.31+191.1%
Shares Out78.57M
PE Ratio65.66
Forward PE44.78
Dividendn/a
Ex-Dividend Daten/a
Volume545,145
Open$93.91
Previous Close$93.53
Day's Range$92.95 - $95.23
52-Week Range$37.02 - $99.31
Beta0.08
AnalystsBuy
Price Target$97.40(+3.73%)
Earnings DateFeb 23, 2027

About KNSA

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.

Address
105 Piccadilly, London, GL, W1J 7NJ, GB
Market Cap
7.38 billion
Employees
366
Industrial Classification
Medical - Pharmaceuticals

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$40.21M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
4 Buy0 Hold0 SellAvg target $87.00 (-7.3%)

4 firms rating KNSA in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Strong
From KNSA’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
+0.38%
5 Days
-2.87%
1 Month
+17.81%
6 Months
+75.01%
1 Year
+125.82%

$KNSA stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in KNSA holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by KNSA's directors and management

Net Shares Purchased by Insiders−500k−250k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

KNSA Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New KNSA patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to KNSA from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in KNSA

IWMiShares Russell 2000 ETF$111.88M
VTIVanguard Morningstar Total Stock Market ETF$101.36M
VBVanguard Morningstar Small-Cap ETF$89.89M
VBKVanguard Morningstar Small-Cap Growth ETF$50.31M
IWOiShares Russell 2000 Growth ETF$40.49M
DFASDimensional - US Small Cap ETF$29.66M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from KNSA’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
96
News & Sentiment
20% of score
58

News check: Analyst upgrades and growth catalysts outweigh routine insider selling and conference presentation activity.

Recent Insider Activity

Buys
0
Sells
16
Buy Value
$0
Distinct Buyers
0

Insider Score Trend Over Time

+0.0 since Sep 25
0255075100Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 26.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Sep 25Sep 29Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

HYPGolden Eagle Dynamic Hypergrowth ETF2.83%
AFSCabrdn Focused U.S. Small Cap Active ETF2.64%
BBPVirtus Biotech ETF2.37%
FFTYCapForce IBD 50 ETF2.32%
FORHFormidable ETF1.39%
HELXFranklin Genomic Advancements ETF1.21%
EHLSEven Herd Long Short ETF1.11%
SMCFThemes US Small Cap Cash Flow Champions ETF1.10%
JSMLJanus Henderson Small Cap Growth Alpha ETF1.02%
AFSMFirst Trust Active Factor Small Cap ETF0.92%
ABLSAbacus FCF Small Cap Leaders ETF0.87%
NTRLFirst Trust Merger Arbitrage ETF0.76%

Weight is the stock’s share of each fund’s holdings.